KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBIT: 2014-2024

Historic EBIT for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to -$568.2 million.

  • BeOne Medicines' EBIT rose 235.63% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 120.94%. This contributed to the annual value of -$568.2 million for FY2024, which is 52.95% up from last year.
  • BeOne Medicines' EBIT amounted to -$568.2 million in FY2024, which was up 52.95% from -$1.2 billion recorded in FY2023.
  • In the past 5 years, BeOne Medicines' EBIT ranged from a high of -$568.2 million in FY2024 and a low of -$1.8 billion during FY2022.
  • For the 3-year period, BeOne Medicines' EBIT averaged around -$1.2 billion, with its median value being -$1.2 billion (2023).
  • In the last 5 years, BeOne Medicines' EBIT soared by 59.19% in 2021 and then tumbled by 164.57% in 2022.
  • Yearly analysis of 5 years shows BeOne Medicines' EBIT stood at -$1.7 billion in 2020, then skyrocketed by 59.19% to -$676.4 million in 2021, then crashed by 164.57% to -$1.8 billion in 2022, then skyrocketed by 32.52% to -$1.2 billion in 2023, then surged by 52.95% to -$568.2 million in 2024.